The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that progressed on standard therapy. The next phase of a clinical trial will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback